CRIP1 and neoplasm: The combination of anti-programmed cell death ligand 1 (PD-L1) treatment and SX-682 increased CD8+ T-cell infiltration and enhanced anti-tumor activity in CRIP1-overexpressing mice, indicating that CRIP1-involved signaling pathways are critical for tumor immune escape and TME formation.